Newsroom

DENVER--(BUSINESS WIRE)--Dear Fellow Shareholders, With the filing of our 2025 Form 10-K, we want to clearly articulate what the financials reflect—and, importantly, what they do not yet capture. The 10-K captures NUBURU as it was for the financial year ended 31 December 2025. Since the financial year end, NUBURU has successfully executed its restructuring, refinancing and key strategic initiatives and investments. These have helped to ensure that NUBURU is well-positioned to continue to furthe...

LOS ANGELES--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALDX...

NEW YORK--(BUSINESS WIRE)--Vince Holding Corp., (Nasdaq: VNCE) (“VNCE” or the “Company”), a global retail platform, today announced that it plans to report its fourth quarter and fiscal year 2025 financial results pre-market on Wednesday, April 15, 2026. The Company also plans to hold a conference call to discuss its financial results on the same day at 8:30 a.m. ET. During the conference call, the Company may answer questions concerning business and financial developments, trends and other bus...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)...

LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leading human-centric AI and humanoid robot manufacturer, announces the planned delivery of 19 robots and corresponding AI implementations for the months of March, April, and May of 2026. The company continues to develop its pipeline of orders as it moves to scale its production capacity and increase demand for its humanoids and AI. “Realbotix is solving one of the most i...

MIDLAND, Texas--(BUSINESS WIRE)--New Era Energy & Digital, Inc. (Nasdaq: NUAI) (“New Era” or the “Company”), a developer and operator of next-generation digital infrastructure and integrated power assets in the Permian Basin, today announced that it has entered into a non-binding letter of intent (“LOI”) to form a joint venture for the development and financing of its Texas Critical Data Centers campus (“TCDC”) in West Texas. The joint venture will bring New Era together with Stream Data Ce...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab’s investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen’s IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-stage small cell lung canc...

MT. LAUREL, N.J.--(BUSINESS WIRE)--InTest Corporation (NYSE American: INTT), a global supplier of innovative test and process technology solutions for use in manufacturing and testing in key target markets which include Semiconductor, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, and Safety/Security, today announced that Rich Rogoff, Division President of InTest’s Environmental Technologies Division, has also been named President and Chief Executive Officer of InTest Corporation and ap...

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”) operates one of Canada’s largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain medical services markets, announced today that it intends to settle an aggregate amount of $420,000 of indebtedness (the “Debt”) owing to Joseph Walewicz, the Company’s former Chief Executive Offic...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FD...